Merck & Company Inc (MRK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $364.26B
Last updated: Nov 17, 2026 at 11:06 AM ET
Merck & Company Inc (MRK) Stock Forecast
Analysts expect Merck & Company (MRK) to earn $2.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $67.24B. Of 28 analysts, 19 rate the stock Buy or Strong Buy, 9 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 17 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.14, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 68% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 17.9% |
| Buy | 14 | 50.0% |
| Hold | 9 | 32.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 223.0% and revenue estimates rise 3.3%.
- Fiscal year ending Dec 31, 2026
- $2.78
- EPS consensus, revenue $67.24B
- Fiscal year ending Dec 31, 2027
- $8.98
- EPS consensus, revenue $69.46B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.78 | $2.50 to $2.99 | 26 | $67.24B | $66.84B to $67.75B | 25 |
| Dec 31, 2027 | $8.98 | $8.45 to $9.75 | 25 | $69.46B | $67.60B to $72.03B | 25 |
Quarterly Estimates
The EPS consensus rises from $1.76 for the quarter ending Dec 31, 2026 to $2.13 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.76 | $1.67 to $2.01 | 19 | $16.45B | $15.60B to $17.60B | 18 |
| Mar 31, 2027 | $2.13 | $1.97 to $2.27 | 9 | $16.45B | $16.14B to $16.82B | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 19 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 17 | 4 |
| Quarter ending Mar 31, 2027 | 2 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.5% from $2.74.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.78 | $2.77 | $2.69 | $2.75 | $2.74 | +1.4% |
| Fiscal year ending Dec 31, 2027 | $8.98 | $9.02 | $9.32 | $9.55 | $9.55 | -5.9% |
| Quarter ending Mar 31, 2027 | $2.13 | $2.13 | $2.16 | $2.21 | $2.21 | -3.5% |
Frequently Asked Questions About MRK
What is the MRK stock forecast?
Consensus analyst estimates put Merck & Company's EPS at $2.78 for the fiscal year ending Dec 31, 2026, on revenue of $67.24B. The consensus rating from 28 analysts is Buy.
How do analysts rate MRK stock?
Of 28 analysts covering Merck & Company, 5 rate it Strong Buy, 14 Buy, 9 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MRK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.78, with estimates from $2.50 to $2.99 from 26 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $8.98, with estimates from $8.45 to $9.75 from 25 analysts.
What revenue do analysts expect from Merck & Company next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $67.24B, with estimates from $66.84B to $67.75B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $69.46B, with estimates from $67.60B to $72.03B.
How many analysts cover MRK?
28 analysts rate Merck & Company stock, and 26 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MRK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts